Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a note issued to investors on Friday. The firm set a “hold” rating on the stock.

Several other research analysts have also recently commented on ONCT. Northland Capmk cut Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. HC Wainwright cut their price target on Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Brookline Capital Management reiterated a “hold” rating on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Finally, Northland Securities reiterated a “market perform” rating and issued a $2.00 price target on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $20.00.

Oncternal Therapeutics Price Performance

Shares of NASDAQ ONCT opened at $1.35 on Friday. Oncternal Therapeutics has a 1-year low of $1.05 and a 1-year high of $13.14. The business has a 50-day moving average of $2.76 and a 200-day moving average of $6.23. The company has a market capitalization of $4.00 million, a price-to-earnings ratio of -0.11 and a beta of 1.36.

Oncternal Therapeutics (NASDAQ:ONCT) last released its quarterly earnings results on Thursday, August 8th. The company reported ($2.89) EPS for the quarter, topping the consensus estimate of ($3.03) by $0.14. Oncternal Therapeutics had a negative return on equity of 136.10% and a negative net margin of 1,948.70%. The business had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $0.24 million. During the same quarter in the previous year, the firm posted ($3.00) earnings per share. Research analysts expect that Oncternal Therapeutics will post -12.43 EPS for the current fiscal year.

Institutional Trading of Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC acquired a new stake in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned approximately 0.84% of Oncternal Therapeutics as of its most recent SEC filing. Institutional investors own 16.05% of the company’s stock.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.